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Introduction: High collision-risk physical activity can increase bleeding risk in people with 
hemophilia A, as can increasing the time between factor VIII (FVIII) administration and physical 
activity. FVIII prophylaxis may be tailored to planned activities to prevent activity-related bleeding.
Aim: To explore the relationship between physical activity levels, FVIII infusion timing, and 
occurrence of bleeding in patients with severe/moderately severe hemophilia A without FVIII 
inhibitors receiving antihemophilic factor (recombinant) (rAHF; ADVATE®; Baxalta US 
Inc., a Takeda company, Lexington, MA, USA).
Methods: SPACE was a 6-month, prospective, multicenter, observational outcomes study 
(NCT02190149). Enrolled patients received an eDiary application and a wearable activity 
tracker, which recorded physical activity, rAHF infusion, and occurrence of bleeding. 
Physical activity risks were ranked using National Hemophilia Foundation criteria.
Results: Fifty-four patients aged 11–58 years (n = 47 prophylaxis, n = 7 on-demand) were 
included in the analysis. Patients had a mean (SD) 8.14 (10.94) annualized bleeding rate, and 
recorded 4980 intervals between an rAHF infusion and physical activity; 1759 (35.3%) of 
these intervals were ≤24 hours. Analysis of recorded eDiary data showed that the risk of 
activity-related bleeding did not significantly increase with time between last infusion and 
activity, but did increase with higher-risk physical activities. Analysis of activity tracker 
recorded data showed that the risk of bleeding reported by patients as spontaneous increased 
with prolonging time (≤24 to >24 hours) from last infusion to physical activity start (odds 
ratio 2.65, p < 0.05). Joint health data collected at baseline were not included in the 
regression analysis because of small sample size; therefore the study could not assess 
whether patients with more joint disease at baseline were at higher risk of injury-related 
and reported spontaneous occurrence of bleeding.
Conclusion: These results show that activities with a high risk of collision lead to an 
increased risk of bleeding. Further investigation is warranted to explore potential benefits of 
FVIII infusion timing to reduce the risks of activity-related occurrence of bleeding.
Keywords: hemophilia A, recombinant factor VIII, physical activity, post-authorization 
study, prophylaxis, bleeding
Introduction
In people with hemophilia A (PwHA), prophylactic factor VIII (FVIII) replacement 
therapy has been the standard of care for bleeding prevention by maintaining 
plasma FVIII activity levels of ≥1%.1,2 The World Federation of Hemophilia 
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(WFH) 2020 guidelines recommend FVIII activity levels 
of ≥3%.3 FVIII prophylaxis reduces frequency of bleeding 
with the goal of improving quality of life in PwHA.4–6 
Individualized prophylactic regimens that aim to tailor 
FVIII levels to lifestyle and physical activity requirements 
are likely to offer further beneficial effects in minimizing 
bleeding risk while facilitating the physical and psychoso-
cial benefits of exercise.7,8
Limited data exist on the relationship between FVIII 
levels and bleeding risk in PwHA and physically active 
lifestyles. Participation in vigorous, high-risk collision 
sports has been associated with a transient increase in 
bleeding risk, with most activity-related episodes mani-
festing within 1 hour of physical activity.9 While tailoring 
FVIII replacement therapy to a patient’s physical activity 
pattern is likely to be beneficial, it has only recently 
become part of routine practice.10 The evolution of hemo-
philia treatment in recent years, including the development 
of extended half-life FVIII products and non-factor repla-
cement therapies,11 has meant that personalization of treat-
ment is now becoming more widespread. Indeed, 
personalization of therapy based on each individual’s 
activities and lifestyle is recommended in the WFH 2020 
guidelines.3
Patient questionnaires have typically been used to 
monitor physical activity in relation to occurrence of 
bleeding in PwHA. The use of commercial activity track-
ers in hemophilia research is limited, but continuous and 
long-term monitoring of activity with activity trackers was 
suitable in PwHA in an observational prospective study.12 
Mobile applications for recording and monitoring occur-
rence of bleeding and dosing regimens offer an innovative 
method of data collection in clinical studies, with applica-
tions in telehealth for promoting appropriate use of clot-
ting factors in patients with hemophilia.13
The prospective non-interventional Study of 
Prophylaxis, ACtivity and Effectiveness (SPACE) 
explored the effect of physical activity levels and timing 
of antihemophilic factor (recombinant) (rAHF; 
ADVATE®; Baxalta US Inc., a Takeda company, 
Lexington, MA, USA) infusion on occurrence of bleeding 
in patients with hemophilia A.
Materials and Methods
Study Design and Conduct
This prospective, multicenter, post-authorization, 6-month, 
observational outcomes study (NCT02190149) was 
conducted at 21 centers in the United States from 
June 2014 to June 2016. The study was approved by 
independent ethics committees for all participating sites 
and conducted in accordance with standards of good clin-
ical practice in effect at the time of the study and the 
Declaration of Helsinki. All patients (or their legally 
authorized representatives) were provided with informa-
tion about the purpose of the study and gave written 
consent before enrolment.
Patients
Inclusion criteria were: patients aged 13–65 years with 
severe or moderately severe hemophilia A (FVIII ≤2%), 
receiving rAHF and with a history of plasma-derived or 
recombinant FVIII replacement therapy for ≥150 exposure 
days. Patients with hemophilia B (factor IX [FIX] ≤2%) 
receiving recombinant factor IX, nonacog gamma (BAX 
326, Rixubis®; Baxalta US Inc., a Takeda company, 
Lexington, MA, USA) were also eligible, but those results 
are not reported here. Patients with an inhibitor titer of 
≥0.6 Bethesda units, or being treated for an inhibitor, or 
who had elective surgery planned within 6 months after 
enrolment that might interfere with daily activities, or 
those continuously requiring walking assistance devices 
were not eligible for enrolment.
Procedures
At baseline, investigators recorded treatment regimens 
(prophylaxis vs on-demand) and infusion timing schedules 
for patients receiving prophylactic rAHF (routine prophy-
laxis: 20–40 IU/kg every other/every third day; dosage 
targeted to maintain FVIII trough levels ≥1%).13 Patients 
remained on rAHF treatment as directed by their physician 
throughout this non-interventional study (12-month 
recruitment period, 6-month observation period). Patients 
received a customized eDiary smartphone application 
(Exco InTouch, an ERT company, Nottingham, United 
Kingdom) and a wearable activity tracker (Fitbit®; Fitbit, 
Inc., San Francisco, CA, USA), which recorded data dur-
ing the observation period (ie, period between eDiary/ 
activity tracker start and end dates) and at study comple-
tion (Figure 1A). The eDiary application was downloaded 
onto the patient’s smartphone and served as the primary 
data collection tool for patient physical activity, infusion 
timing, and occurrence of bleeds; if the patient did not 
have access to a suitable phone, one was provided for the 
study duration. During the observation period, upon occur-
rence of a bleeding episode, patients recorded in the 
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• Moderately severe or severe  
 hemophilia A (FVIII level ≤2%)
• Aged 13-65 years
• Receiving rFVIII
• Prior treatment with FVIII ≥150 EDs
Baseline CRF (investigator reported)
• Demographics
• Medical history
• Prescribed treatment regimen
• Bleeding history
• Available joint outcome measurements
• Number of target joints 
• Other¶
eDiary baseline survey (patient reported) 
• Activity levels 
• Satisfaction with activity level
• Bleeding history
HAL or PedHAL questionnaire 
eDiary (patient reported) 
• Treatment (eg, infusion timing)
• Physical activity
• Occurrence of bleeding episodes
Safety calls to patient by site every 
month
Data entry reminder phone calls to 
patients as needed
eDiary survey 
• Changes in treatment regimen
• Activity level









6-month observation period Study completion
Figure 1 (A) SPACE study design and timing of assessments. (B) Patient disposition. †For inactivity (n = 1), loss to follow-up (n = 1), non-compliance with required 
reporting (n = 1), or non-compliance with data entry (n = 1). ‡Technical problems, difficulty committing time (n = 6); non-compliance, withdrew consent (n = 5). §Non- 
compliance (n = 1) and technical difficulties (withdrawn per protocol; n = 2). ¶Other data includes number of concomitant medications, non-drug therapies and available 
pharmacokinetic data history. ††Completed 1 week before study end. 
Abbreviations: CRF, case report form; ED, exposure day; FVIII, factor VIII; HAL, Hemophilia Activities List; PedHAL, Paediatric Hemophilia Activities List; rFIX, 
recombinant factor IX; rAHF, antihemophilic factor (recombinant); SAE, serious adverse event.
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eDiary the doses and reasons for infusions (routine pro-
phylaxis or on-demand [ie, treatment for new occurrence 
of bleeding]). Lastly, the patients captured changes in 
treatment regimen at the time of study completion. Data 
collected via the activity tracker included steps taken and 
active minutes. Additionally, upon activity-related occur-
rence of bleeding, patients indicated what type of activity 
was associated with the occurrence of bleeding.
Objectives
The primary study objective was to explore the relation-
ship between physical activity level, rAHF infusion tim-
ing, and occurrence of bleeding episodes in PwHA during 
a 6-month observation period. Secondary objectives 
included collecting physical activity data (type, frequency) 
using a patient self-reported eDiary and a consumer-based 
activity tracker.
Data Collection and Analyses
Estimation of Time Since Last Infusion to Start of 
Activity
To estimate the time (ie, number of hours) since the last 
rAHF infusion to the start of physical activity, each day 
was divided into the following four 6-hour cycles: 
Morning, 06:00 to 12:00; afternoon, >12:00 to 18:00; 
evening, >18:00 to sleep; and night, 24:00 to <06:00.
Physical Activity
At baseline, patients documented in the eDiary the physi-
cal activity type, average number of days per week spent 
participating at each risk level, barriers to participation, 
and information on FVIII infusions before planned activ-
ities. Patients rated their activities in the eDiary according 
to the National Hemophilia Foundation “Playing it safe” 
activity listing, which identifies a risk collision score asso-
ciated with various activities; if an activity was not listed, 
patients were asked to estimate the risk level.14 Activities 
were thus classified into one of the following three cate-
gories based on the associated risk: (1) significant colli-
sions are not expected; (2) significant collisions might 
occur, and (3) significant collisions are inevitable. During 
the observation period, patients recorded type, duration, 
and timing of activities undertaken daily in the eDiary. 
Timing of physical activity was recorded as a time range 
(ie, not the exact time); for the purposes of the analysis, 
the “morning” time range was set to start at 06:00 (morn-
ing), the “afternoon” time range at 12:00 (noon) and the 
“night” range at 18:00 (night). The activity tracker 
recorded daily totals for steps taken and active minutes.
Occurrence of Bleeding
At baseline, patients recalled from memory the number 
and location of occurrences of bleeding (eg, total and joint 
bleeds) during the 6 months before the date of informed 
consent, as well as the number and location of target 
joints, which were recorded on the case report form. 
Information on bleed history was also compiled from 
patient medical records. During the study’s 6-month obser-
vation period, patients recorded location, cause (any, activ-
ity-related, spontaneous, or other), type (joint or non- 
joint), and duration of occurrence of bleeding in the 
eDiary (retrospective entry for previous 2 days of data 
was permitted). If no end date was recorded for 
a bleeding episode, the study site followed up with the 
individual for bleed status. If the patient did not record/ 
report bleed or infusion timing data during the allowed 
window of time, the data were considered missing. Only 
observed data were used in the analysis.
The number of bleeding episodes that happened during 
the study period was summarized by treatment regimen 
(prophylaxis or on-demand) vs type of bleed and by age 
group vs bleed type. Bleed frequency, annualized bleeding 
rate (ABR), and annualized joint bleeding rate (AJBR) 
were calculated for patient-level data.
Safety
From the time of informed consent to study completion, 
patients reported serious adverse events (SAEs) directly to 
study sites (ie, not in the eDiary); additional safety infor-
mation was collected during follow-up calls every other 
month. SAEs included medical occurrences where the out-
come was fatal, life-threatening, required inpatient hospi-
talization, or was a medically important event. AEs were 
categorized according to the Medical Dictionary for 
Regulatory Activities (version 19.0). The potential causal 
relationship between rAHF treatment and an SAE was also 
evaluated.
Treatment Adherence
Measures of adherence to prophylactic treatment during 
the 6-month observation period included dose adherence 
(proportion of total prescribed dose actually administered) 
and infusion timing schedule adherence vs baseline regi-
men. Infusion schedule was calculated both as 
a proportion of planned infusions administered and 
a proportion of planned infusions administered on 
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schedule (within a 1-day window). All parameters were 
reported as means (SDs) of proportions.
Compliance to Data Entry
Data entry compliance was calculated as proportion of 
days during the observation period with complete entries. 
Patients received a motivational phone call every other 
month to ensure data entry compliance. Individuals with 
no recorded data for 2 consecutive weeks or for a total of 3 
weeks were withdrawn from the study. Compliance was 
categorized by quintiles.
Data Collection Procedures
Patients were trained to use an integrated web portal (Exco 
InTouch database), which linked to the eDiary and activity 
tracker data. Data from the eDiary were automatically 
exported to the clinical database. Patients had to sync 
their activity tracker data to the web portal daily if their 
smartphone did not have the required capabilities for auto-
matic syncing. A reminder message was sent to patients 
after a few days if they forgot to connect their activity 
tracker.
Statistics
To obtain 50 evaluable patients, the enrolment target was 
60 patients. Because study objectives were exploratory, no 
formal power calculations were performed to determine 
sample size. Results were summarized by treatment regi-
men using descriptive statistics (Table S1 includes vari-
ables and subgroup definitions used in the analysis). The 
safety population comprised all patients who were treated 
with ≥1 rAHF dose. The full analysis set (FAS) population 
comprised patients in the SAS with valid eDiary activity 
data recorded.
Longitudinal logistic regression models were used to 
evaluate the dynamic association between physical activity 
levels, time since last infusion to start of physical activity 
cycle, and activity-related bleeding risk of patients in the 
FAS, regardless of treatment discontinuation. eDiary and 
activity tracker data were analyzed separately. Covariates 
are described in Table S1. Occurrence of bleeding epi-
sodes in each cycle was modelled as a binary dependent 
variable, and outcomes were expressed as the odds of 
bleeding in a given situation (odds ratio [OR] [95% con-
fidence interval (CI)]) vs in absence of the situation (activ-
ity vs no activity). For safety data, p-values were 




Of 64 patients enrolled, 60 with hemophilia A receiving 
rAHF were eligible and 54 had both activity and rAHF 
infusion data recorded in the eDiary (FAS). Forty-two 
patients completed the study; 3 failed screening and 19 
discontinued prematurely (Figure 1B). Information on data 
entry compliance for both eDiary and activity tracker 
entries was available for 53/54 patients, of whom 16 
(30.2%) had entries for ≥60% of observation days 
(Table S2).
Mean (SD) age at screening was 23.7 (12.1) (range 
11.0–58.0) years (Table 1). One patient in the FAS was 
younger than the lower age limit for study eligibility (13 
years) and received a waiver to permit enrolment. Patients 
had a mean (SD) 5.0 (9.0) bleeding episodes (all bleeds) in 
the 6 months before providing informed consent. The 
majority of patients (47/54) received prophylaxis. The 
most common prophylactic dosing schedule at baseline 
and during the observation period was three infusions per 
week (n = 26, 55.3%), then infusions every second day (n 
= 8, 17.0%), then twice per week (n = 7, 14.9%). One 
patient in each regimen group at baseline switched regi-
mens during the study.
Physical Activity
Physical activity intensity data recorded via the eDiary 
were available for 54 patients at baseline and 34 at study 
completion. In the 6-month pre-observation period, mean 
(SD) number of days per week spent on mild, moderate, 
and strenuous activity was 2.74 (2.29), 2.30 (1.70), and 
1.65 (1.75), respectively. At study completion, mean (SD) 
number of days spent on each activity per week was 2.50 
(2.29), 2.50 (1.80), and 2.35 (1.95) days, respectively 
(Table 2). Of 34 evaluable patients with available physical 
activity data at study completion, 29 (85.3%) patients 
reported that they infused prior to activity (27/31 patients 
on prophylaxis; 2/3 on-demand regimen).
Among all 54 patients (prophylaxis or on-demand 
treatment) during the 6-month observation period, there 
were 4980 total intervals recorded between an rAHF infu-
sion and the next recorded physical activity (morning, 
noon, or night). Overall, patients administered most infu-
sions >24 hours before initiating activity (64.7%, 3221/ 
4980 intervals); 479 (9.6%) intervals were ≥5 days. 
Overall, 27.8% of patients infused 1–2 days before starting 
an activity; the proportion was consistent across the 
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activity risk level categories. Of 4980 total intervals, 3761 
(75.5%) were associated with low-risk activities and 196 
(3.9%) with high-risk activities (Table 3).
Occurrence of Bleeding
During the 6-month observation period, 17/54 (31.5%) 
patients reported no bleeding episodes (Table S3). The 
Table 1 Patient Baseline Characteristics
Treatment Regimen
Characteristic Total N = 54 On-Demand n = 7† Prophylaxis n = 47†
Age, y, mean ± SD 23.7 ± 12.1 26.6 ± 17.9 23.3 ± 11.3
Race, n (%)
White 44 (81.5) 6 (85.7) 38 (80.9)
Black 7 (13.0) 0 (0) 7 (14.9)
Asian 3 (5.6) 1 (14.3) 2 (4.3)
Body mass index, kg/m2 mean ± SD‡ 25.0 ± 7.3 20.2 ± 5.8 25.7 ± 7.3
No. of bleeding events per patient during the 6 months before enrollment, median (min–max)
All bleeding events 2 (0.0–60.0) 3 (0.0–60.0) 2 (0.0–16.0)
Type‡
Joint 1 (0.0–30.0) 3 (0.0–30.0) 1 (0.0–14.0)
Non-joint 0 (0.0–30.0) 1 (0.0–30.0) 0 (0.0–15.0)
Cause
Spontaneous 0 (0.0–15.0) 0 (0.0–7.0) 0 (0.0–15.0)
Activity-related 0 (0.0–60.0) 1 (0.0–60.0) 0 (0.0–16.0)
Unknown 0 (0.0–3.0) 0 (0.0–1.0) 0 (0.0–3.0)
Total no. of target joints per patient at screening, mean ± SD 0.6 ± 1.4 0.6 ± 1.5 0.6 ± 1.4
Notes: †One patient, who was treated with prophylaxis at baseline, received only one on-demand treatment during the observation period and was included in the on-demand 
group. One patient who was treated on-demand at baseline changed to prophylaxis treatment. ‡Based on a total of 53 patients (on-demand, n = 7; prophylaxis, n = 46).
Table 2 Physical Activity Duration and Intensity at Baseline and Study End (eDiary Data)
Treatment Regimen
Total On-Demand Prophylaxis
Baseline (during the 6 months before the study)
Patients, n 54 7 47
Days per week by intensity level, mean ± SD
Strenuous 1.65 ± 1.75 2.57 ± 2.44 1.51 ± 1.61
Moderate 2.30 ± 1.70 2.57 ± 1.90 2.26 ± 1.69
Mild 2.74 ± 2.29 1.71 ± 2.06 2.89 ± 2.31
Study end
Patients, n 34 3 31
Days per week by intensity level, mean ± SD
Strenuous 2.35 ± 1.95 1.67 ± 0.58 2.42 ± 2.03
Moderate 2.50 ± 1.80 2.33 ± 0.58 2.52 ± 1.88
Mild 2.50 ± 2.29 0.33 ± 0.58 2.71 ± 2.28
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remaining 37 patients reported 185 bleeding episodes in 
total. Overall (n = 54), mean (SD) number of bleeds per 
person was 3.43 (5.06) for all bleeds, of which 1.52 (2.94) 
were reported by patients as spontaneous and 1.39 (2.11) 
as related to physical activity. For 31 patients receiving 
prophylaxis, there were 3.02 (4.72) bleeds per person (1.21 
[2.41] reported by patients as spontaneous, and 1.26 [2.03] 
reported as activity-related); for six patients receiving on- 
demand treatment, there were 6.14 (6.77) bleeds per per-
son (3.57 [5.13] reported as spontaneous and 2.29 [2.63] 
reported as activity-related).
At study end, mean (SD) ABR for all bleeds was 8.14 
(10.94) among patients with ≥5 months of data during the 
observation period. ABR for all bleeds was higher for 
Table 3 rAHF Infusions by Time from Most Recent Infusion Before Start of Physical Activity Based on NHF Activity Risk Level (eDiary 
Data)
NHF Activity Risk Level
Total N = 54 1 (Low) 1.5 (Low to 
Moderate)




included in analysis, n†
4980 3761 488 935 330 196
Time between infusion and start of activity, n (%)
≤8 h 560 (11.2) 412 (11.0) 79 (16.2) 122 (13.0) 32 (9.7) 26 (13.3)
8–12 h 310 (6.2) 246 (6.5) 28 (5.7) 61 (6.5) 27 (8.2) 13 (6.6)
12–24 h 889 (17.9) 710 (18.9) 55 (11.3) 148 (15.8) 76 (23.0) 44 (22.4)
1–2 d 1382 (27.8) 1047 (27.8) 130 (26.6) 283 (30.3) 92 (27.9) 52 (26.5)
2–3 d 802 (16.1) 632 (16.8) 74 (15.2) 124 (13.3) 37 (11.2) 33 (16.8)
3–5 d 558 (11.2) 411 (10.9) 57 (11.7) 98 (10.5) 31 (9.4) 19 (9.7)
≥5 d 479 (9.6) 303 (8.1) 65 (13.3) 99 (10.6) 35 (10.6) 9 (4.6)
Notes: †eDairy recorded time of infusions but not activity time. It was assumed that the activity occurred in the morning at 6 AM, afternoon at 12 PM, and night at 6 PM. 



















































































Figure 2 Annualized bleeding rates (ABR) at study end by treatment regimen. (A) All bleeds. (B) Joint bleeds. †Patients with ≥5 months of follow-up data. 
Abbreviation: AJBR, annualized joint bleeding rate.
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patients receiving on-demand therapy vs prophylaxis 
(Figure 2A). AJBR was 4.09 (8.05) overall, with 
a higher AJBR observed for patients receiving on- 
demand treatment vs prophylaxis (Figure 2B).
Safety
Overall, 10 AEs, of which 7 were SAEs, were reported in 
7 patients (all on prophylaxis); none of these AEs or SAEs 
were considered related to rAHF. The proportion of 
patients experiencing AEs did not differ significantly 
between age groups (Table S4).
Treatment Adherence and rAHF 
Consumption
For dose adherence assessment, the mean (SD) propor-
tion of total rAHF dose received vs dose prescribed 
was 0.65 (0.31). For schedule adherence, the mean 
(SD) proportion of infusions received on schedule vs 
infusions planned was 0.48 (0.32) based on gap 
between infusions and 0.64 (0.28) based on number 
of infusions (Table 4); 19.1% (9/47) of patients 
received 80–100% of the prescribed prophylactic 
rAHF dose and 19.1% (9/47) received 80–100% of 
planned infusions (based on gap between infusions). 
Individuals aged ≥18 years were more adherent to 
prophylactic rAHF than those aged <18 years, with 
statistically significant differences for schedule adher-
ence but not dose adherence (Table 4).
Risk of Physical Activity-Related and 
Spontaneous Bleeds
According to data recorded in the eDiary, activity-related 
bleeding risk tended to increase commensurately with phy-
sical activities classified as higher risk (odds of activity- 
related bleeding for level 3 risk activity were 5 times that 
for no activity in those receiving prophylaxis; OR [95% CI] 
5.06 [1.33–19.27], p = 0.0173; Table 5A). There was no 
significant correlation between bleeds recorded in the 
eDiary as activity-related and the time since last rAHF 
infusion.
Regression analysis of activity tracker data showed no 
significant relationship between odds of physical activity- 
related occurrence of bleeding with either physical activity 
type or time between last rAHF infusion and start of 
physical activity (Table 5B), although prolonging time 
from last rAHF infusion to start of physical activity from 
≤24 to >24 hours was significantly associated with higher 
risk of bleeding reported by patients as spontaneous (OR 
range, 2.61–2.65; all p < 0.05; Table 6).
Discussion
This study was designed to elucidate the temporal relation-
ship between physical activity levels, FVIII infusion timing, 
and occurrence of bleeding episodes in adolescents and 
adults with hemophilia A who were prescribed rAHF in the 
United States. As expected, a higher-risk physical activity 
correlated with greater probability of bleeding reported as 
physical activity-related. However, eDiary and activity 
Table 4 Treatment Adherence to Prophylaxis
Age Group
Parameter Total Age <18 y Age ≥18 y p- 
value
Adherence to dose: Proportion of total prescribed dose administered
Patients, n 43† 19 24
Mean ± SD 0.65 ± 0.31 0.55 ± 0.26 0.73 ± 0.33 0.0547
Adherence to schedule (gap between infusions): Proportion of planned infusion administered 
according to schedule within a 1-day window
Patients, n 47 21 26
Mean ± SD 0.48 ± 0.32 0.36 ± 0.27 0.57 ± 0.33 0.0351
Adherence to schedule (number of infusions): Proportion of planned infusions administered 
according to schedule within a 1-day window
Patients, n 47 21 26
Mean ± SD 0.64 ± 0.28 0.53 ± 0.21 0.73 ± 0.29 0.013
Note: †Five patients were not included due to missing data.
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Table 5 Effect of Physical Activity and Time Since Last rAHF Infusion to Start of Activity on Risk of Bleeding Events Reported as 
Activity-Related by Patients with Hemophilia A Receiving Prophylactic rAHF: Logistic Regression Model Based on Data from the (A) 
eDiary and (B) Activity Tracker
A. eDiary data (N = 47)†,‡
Parameter Odds ratio 95% CI p-value
Model 1: Activity vs no activity
Activity: Yes vs no 1.74 0.81–3.77 0.1571
Time since last infusion to activity start§:
12–24 vs ≤12 h 1.17 0.53–2.59 0.6966
>24 vs ≤12 h 1.00 0.36–2.77 0.9928
Last infusion dose, IU/kg 1.00 0.98–1.02 0.9030
Model 2: Physical activity by risk level
Activity level¶
Risk levels 1 and 1.5 vs no activity 1.65 0.77–3.56 0.2006
Risk levels 2 and 2.5 vs no activity 1.92 0.83–4.44 0.1255
Risk levels 3 vs no activity 5.06 1.33–19.27 0.0173
Time since last infusion to activity start§:
12–24 vs ≤12 h 1.13 0.51–2.51 0.7696
>24 vs ≤12 h 1.01 0.37–2.75 0.9892
Last infusion dose, IU/kg 1.00 0.97–1.02 0.8697
Model 3: Time spent on physical activities
1–30 min of activity vs no activity 1.47 0.56–3.82 0.4331
31–60 min of activity vs no activity 1.95 0.71–5.36 0.1938
>60 min of activity vs no activity 2.92 0.94–9.14 0.0650
Time since last infusion to activity start§:
12–24 vs ≤12 h 1.15 0.53–2.51 0.7265
>24 vs ≤12 h 1.02 0.37–2.77 0.9757
Last infusion dose, IU/kg 1.00 0.97–1.02 0.8794
Age 0.95 0.89–1.01 0.1152
Model 4: Time spent on the physical activity by risk level
Every 30 min spent on activity risk levels 1 and 1.5 1.03 1.01–1.04 0.0043
Every 30 min spent on activity risk levels 2 and 2.5 1.05 0.93–1.18 0.4673
Every 30 min spent on activity risk level 3 1.23 1.18–1.29 <0.0001
Time since last infusion to activity start§:
12–24 vs ≤12 h 1.20 0.55–2.62 0.6423
>24 vs ≤12 h 1.02 0.38–2.72 0.9648
Last infusion dose, IU/kg 1.00 0.97–1.02 0.8039
Age 0.96 0.91–1.01 0.1415
Model 5: Time spent on common physical activities
Every 30 min spent on common activities
Walking (risk level 1) 1.19 1.08–1.30 0.0002
Body sculpting (risk level 1.5) 1.61 1.00–2.59 0.0502
Running and jogging (risk level 2) 2.09 1.31–3.32 0.0019
(Continued)
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Table 5 (Continued). 
Power lifting (risk level 3) 7.58 3.95–14.55 <0.0001
Other activities 1.02 1.00–1.04 0.0658
Time since last infusion to activity start§:
12–24 vs ≤12 h 1.17 0.52–2.62 0.7055
>24 vs ≤12 h 1.01 0.36–2.86 0.9811
Last infusion dose, IU/kg 1.00 0.97–1.02 0.8205
Age 0.95 0.88–1.02 0.1243
B. Activity tracker data (N = 46)†
Parameter Odds ratio 95% CI p-value
Model 1: Activity calories
Activity calories: 1–1000 vs 0 2.75 0.70–10.88 0.1491
Activity calories: >1000 vs 0 3.00 0.77–11.68 0.1124
Time since last infusion to activity start††:   
>24 vs ≤24 h
0.92 0.45–1.88 0.8148
Last infusion dose, IU/kg 0.99 0.96–1.01 0.3102
Age 0.96 0.91–1.02 0.1848
Model 2: Steps performed
Steps: 1–6000 vs 0 2.49 0.64–9.69 0.1891
Steps: >6000 vs 0 3.15 0.81–12.2 0.0975
Time since last infusion to activity start††:   
>24 vs ≤24 h
0.92 0.45–1.88 0.8308
Last infusion dose, IU/kg 0.99 0.96–1.01 0.2959
Age 0.96 0.91–1.02 0.1617
Model 3: Time spent on activities
1–120 min of activity vs no activity 2.57 0.50–13.24 0.2584
121–240 min of activity vs no activity 2.25 0.67–7.62 0.1920
>240 min of activity vs no activity 3.48 0.89–13.63 0.0731
Time since last infusion to activity start††:   
>24 vs ≤24 h
0.92 0.45–1.89 0.8206
Last infusion dose, IU/kg 0.99 0.97–1.01 0.3022
Age 0.96 0.91–1.02 0.1608
Model 4: Time spent on the activity by risk level
Every 30 min spent on lightly active activity 1.03 0.95–1.12 0.4279
Every 30 min spent on fairly active activity 1.06 0.90–1.26 0.4786
Every 30 min spent on very active activity 1.04 0.73–1.47 0.8360
Time since last infusion to activity start††:   
>24 vs ≤24 h
0.91 0.45–1.87 0.8055
Last infusion dose, IU/kg 0.99 0.97–1.01 0.3322
Age 0.96 0.91–1.01 0.1472
Notes: P-values of <0.05 indicate statistically significant associations. †Logistic regression models were used to evaluate the dynamic association between physical activity 
and time since last infusion on bleeding risk with time-varying activity level in the current cycle, time since last rAHF infusion to the beginning of the activity cycle, and age at 
baseline (fixed covariate). Generalized estimating equations were used to account for intra-person correlations. ‡Among the 47 patients receiving prophylaxis, 22 
experienced a total of 50 activity-related bleeding events that were included in this analysis. §eDiary data did not record the exact timing of activities. Time since last 
rAHF infusion was estimated by dividing each day into four cycles (6 AM to 12 PM [morning], 12 PM to 6 PM [afternoon], 6 PM to sleep [evening], 12 AM to 6 AM [night]), 
with activities assumed to start at the beginning of a designated cycle. ¶Risk levels rate from 1 (low) to 3 (high); see Table S1 for more details. ††The activity tracker did not 
record the exact timing of activity but reported the number of activity minutes by risk level daily. Therefore, the data were structured by date for each patient. 
Abbreviation: rAHF, antihemophilic factor (recombinant).
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tracker data did not show that a longer time between last 
rAHF infusion and start of physical activity (≤24 vs > 24 
hours) was associated with significantly greater risk of occur-
rence of bleeding reported by patients as physical activity- 
related. Although most patients infused before physical 
activity, nearly 65% of infusions occurred >24 hours 
(35.3% ≤24 hours) before initiating physical activity. rAHF 
infusion was timed more closely to physical activity and 
occurred more frequently among patients engaging in higher- 
risk activities, although 60% of infusion intervals for level 
2.5–3 activities exceeded 24 hours. Together, these findings 
suggest that less than half of patients adjusted rAHF infusion 
timing for higher-risk physical activities.
The study cohort presented in this analysis represented 
a generally healthy population with hemophilia A, with 
a number of pre-study bleeding episodes comparable with 
that of prophylactically treated patients with severe hemophilia 
A in the United States.15 Time since last infusion was not 
Table 6 Effect of Physical Activity and Time Since Last rAHF Infusion to Start of Activity on the Risk of Bleeding Events Reported as 
Spontaneous by Patients with Hemophilia A Receiving Prophylactic rAHF: Logistic Regression Model (Activity Tracker Data; N = 46)†,‡
Parameter Odds Ratio 95% CI p-value
Model 1: Activity calories
Activity calories: 1–1000 vs 0 2.43 1.01–5.87 0.0484
Activity calories: >1000 vs 0 2.25 0.90–5.62 0.0840
Time since last infusion to activity start§:   
>24 vs ≤24 h
2.65 1.05–6.67 0.0386
Last infusion dose, IU/kg 0.98 0.95–1.00 0.0644
Age 0.99 0.96–1.02 0.4659
Model 2: Steps performed
Steps: 1–6000 vs 0 2.76 1.15–6.62 0.0225
Steps: >6000 vs 0 1.97 0.82–4.72 0.1299
Time since last infusion to activity start§:   
>24 vs ≤24 h
2.65 1.05–6.62 0.0399
Last infusion dose, IU/kg 0.98 0.95–1.00 0.0607
Age 0.99 0.96–1.02 0.5006
Model 3: Time spent on activities
1–120 min of activity vs no activity 2.68 1.06–6.75 0.0368
121–240 min of activity vs no activity 2.28 0.92–5.64 0.0760
>240 min of activity vs no activity 2.19 0.88–5.47 0.0921
Time since last infusion to activity start§:   
>24 vs ≤24 h
2.65 1.04–6.72 0.0409
Last infusion dose, IU/kg 0.98 0.95–1.00 0.0595
Age 0.99 0.96–1.02 0.4855
Model 4: Time spent on the activity by risk level
Every 30 min spent on lightly active activity 1.01 0.94–1.09 0.8197
Every 30 min spent on fairly active activity 1.02 0.80–1.22 0.8308
Every 30 min spent on very active activity 0.92 0.68–1.25 0.5969
Time since last infusion to activity start§:   
>24 vs ≤24 h
2.61 1.02–6.69 0.0452
Last infusion dose, IU/kg 0.98 0.95–1.00 0.0594
Age 0.99 0.96–1.02 0.4492
Notes: P-values of <0.05 indicate statistically significant associations. †Logistic regression models were used to evaluate the dynamic association between activity and time 
since last infusion on bleeding risk with time-varying activity level in the current cycle, time since last rAHF infusion to the beginning of the activity cycle, and age at baseline 
(fixed covariate). Generalized estimating equations were used to account for intra-person correlations. ‡Among the 46 patients in the analysis, 19 had a total of 57 bleeds 
reported as spontaneous. §Activity tracker data did not record the exact timing of activity, but reported the number of activity minutes by risk level daily. Therefore, the data 
were structured by date for each individual. 
Abbreviation: rAHF, antihemophilic factor (recombinant).
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significantly associated with an increased risk of activity- 
related bleeds, and this may be partially explained by patient- 
reported categorization of bleeding types as “any”, “sponta-
neous”, “activity-related”, or “other”. Some patients may have 
had difficulty identifying an occurrence of bleeding as physical 
activity-related vs spontaneous. Therefore, “activity-related” 
occurrence of bleeding may have been under-reported.
The study design did not mandate for exact timing of 
physical activities to be recorded; activity time was 
reported in the eDiary as morning, afternoon, and night 
(the statistical approach to these data was using 6-hour 
cycles), and assumed all activities occurred before bleed-
ing onset. While this methodology may accurately reflect 
the sequence of physical activity and physical activity- 
related occurrence of joint bleeding episodes, it may not 
for other bleeding types (ie, spontaneous, any, and other). 
The 6-hour cycles may therefore have been too imprecise 
to robustly explore the relationship between timing of 
rAHF infusion and physical activity and bleed risk. 
Further, patient entries were retrospective and based on 
memory, thus subject to recall bias.16 In addition, activity 
tracker data may have been skewed towards including 
physically active patients and those interested in tracking 
physical activity. The results may therefore not be indica-
tive of causal relationships and the findings should be 
interpreted with caution. Further, it may suggest that the 
National Hemophilia Foundation “Playing it safe” activity 
listing could predict high-risk activities inaccurately.
Analysis by physical activity level as a group meant 
that data were not skewed by individual patient physical 
activity levels. Nevertheless, further research on patient 
physical activity in relation to FVIII treatment patterns is 
warranted, preferably with inclusion of pharmacokinetic 
data so that correlations between FVIII levels and physical 
activity can be investigated. The small sample size 
of regression models for the physical activity level group 
would likely reduce their ability to control for confounding 
risk factors such as bleeding history.
Although joint health data were collected at baseline, 
they were not included in the regression analysis 
because of small sample size; therefore the study could 
not assess whether patients with more joint disease at 
baseline were at higher risk of injury-related and 
reported spontaneous bleeding. Lastly, only one-third 
of patients were ≥60% compliant with both eDiary and 
activity tracker data entry.
ABRs for all bleeds in this study were similar to 
bleeding rates from other real-world settings,17,18 
although somewhat higher than rates reported at year 3 
of rAHF treatment in the observational AHEAD study,19 
and after ≥5 years of rAHF treatment in the AHEAD 
study.20 This may be explained by suboptimal prophy-
laxis adherence compared with other studies.18 
Hemophilia A treatment adherence rates vary across 
studies due in part to lack of standardized estimation 
methods21 and barriers to prophylaxis adherence in 
a real-world setting.22 In the current study, adolescents 
exhibited worse adherence than adults, which is consis-
tent with findings from elsewhere.23 We observed 
a small number of reported AEs or SAEs, none of 
which were considered related to rAHF.
Conclusions
The findings of this study did not demonstrate that a longer 
time between last rAHF infusion and physical activity start 
was associated with risk of occurrence of bleeding 
reported by patients as physical activity-related. Further 
studies designed to address the limitations herein 
described are needed to confirm the association between 
physical activity level, timing of infusions, and the occur-
rence of bleeding in patients with hemophilia A.
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